Case Report: Avelumab and ruxolitinib to manage polycythemia vera and secondary metastatic Merkel cell carcinoma: a possible successful combination

Frontiers in Oncology

Oncology

Chiara Masucci¹  Mauro Passucci¹  Marcello Capriata¹  Ida Carmosino¹  Claudia Ielo¹  Maurizio Martelli¹  Emilia Scalzulli¹  Massimo Breccia¹  Alessandro Costa² 

[1] Department of Translational and Precision Medicine, Policlinico Umberto I, La Sapienza University of Rome, Rome, Italy;Hematology Unit, Businco Hospital, Azienda di Rilievo Nazionale ed Alta Specializzazione (ARNAS) G. Brotzu, Cagliari, Italy;

关键词: avelumab;    Merkel cell carcinoma;    ruxolitinib;    polycytemia vera;    second malignancies;   

DOI  :  10.3389/fonc.2023.1212638

 received in 2023-04-26, accepted in 2023-05-22,  发布年份 2023

来源: Frontiers

【 摘 要 】

We describe a case of second primary malignancy in a 65-year-old patient affected by polycythemia vera treated with the JAK 1/2 inhibitor ruxolitinib. The latter is recognized as a risk factor for the onset of non-melanoma skin cancers in many retrospective and perspective studies, but the concomitant use of ruxolitinib with new immunotherapies is very rarely reported, and the safety of this association is still not clear. In our case, ruxolitinib combined with the anti-PD-L1 avelumab demonstrated both safety and efficacy for hematological disease control and underlying carcinoma remission.

【 授权许可】

Unknown   
Copyright © 2023 Masucci, Passucci, Scalzulli, Carmosino, Capriata, Costa, Ielo, Martelli and Breccia